ProfileGDS5678 / 1448094_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 38% 38% 38% 36% 41% 43% 37% 37% 38% 38% 37% 38% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9357339
GSM967853U87-EV human glioblastoma xenograft - Control 22.8729138
GSM967854U87-EV human glioblastoma xenograft - Control 32.8715638
GSM967855U87-EV human glioblastoma xenograft - Control 42.8114438
GSM967856U87-EV human glioblastoma xenograft - Control 52.7752436
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0337641
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0727243
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8434137
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8313337
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8553638
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.856338
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8062237
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8747538
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8645538